STAAR Surgical Q2 net sales rise 111% to $93.5 million; net income $8.1 million
STAAR Surgical reported second-quarter 2026 results for the quarter ended July 3, 2026, with net sales of $93.5 million, up from $44.3 million a year earlier, and net income of $8.1 million, or $0.16 per diluted share, compared with a net loss of $16.8 million a year earlier. The filing furnishes the earnings release as Exhibit 99.1 and announces a conference call at 5:30 p.m. Eastern on August 12, 2026, where management will discuss the results. The company reported cash and investments of $181.5 million and no outstanding debt.
Key points
- Net sales of $93.5 million, up 111% year over year; sales excluding China were $41.2 million, up 6.0%
- China sales of $52.3 million; EMEA sales declined by a low single-digit percentage, with growth excluding the Middle East
- Net income of $8.1 million, or $0.16 per diluted share, versus a net loss of $16.8 million, or $0.34 per diluted share, a year ago
- Adjusted EBITDA of $20.0 million, or $0.39 per diluted share; cash and investments of $181.5 million at July 3, 2026
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.